Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Tavapadon in Parkinson's Disease
NCT02373072Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of tavapadon in Parkinson's disease (PD) (2 cohorts), sponsored by Pfizer. Primary endpoints: Number and proportion of subjects with Adverse Events, Number of participants with vital signs data that meet criteria of potential clinical concern and 3 more. Started Mar 2015; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02373072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02373072.